Poolbeg Pharma Is Just One Of 3 British Healthcare AI Stocks
5 Mins Read
The global AI boom is putting fresh pressure on electricity grids, and that matters for healthcare. British hospitals, clinics and drug researchers need reliable computing power to train medical algorithms and run data heavy tools, yet power costs and supply constraints keep biting. Investors looking at UK healthcare AI stocks are watching this closely, and this article highlights three screened companies aiming to tackle medicine with smarter software.
The three UK stocks below are just a small sample of the idea, and the wider screen surfaced 6 more healthcare AI companies with equally compelling stories that are not covered here.
Poolbeg Pharma is a London based clinical stage biopharma group developing POLB 001 for cancer immunotherapy related cytokine release syndrome and influenza, oral GLP 1 obesity and diabetes candidates, plus an in house AI drug discovery program targeting influenza and RSV, with a market value of about £47 million.
Poolbeg Pharma provides focused exposure to AI driven drug discovery in infectious disease, backed by a growing IP estate around POLB 001 and an active CRS clinical trial program. It remains loss making with minimal revenue, so its long term appeal depends on how one crucial funding and data inflection develops.
That hinges on what the next round of data and cashflow looks like, so it is worth lining that up against the 2 warning signs (1 is major!) before forming a view.
AIM:POLB 1-Year Stock Price Chart
IXICO runs AI-enabled neuroimaging services that help drug developers and clinicians read brain scans for Alzheimer’s, Parkinson’s and other neurological diseases, using its IXICO platform and imaging CRO tools. It reported £7.3 million of Medical Labs & Research revenue and carries a market value of about £28.5 million.
IXICO plugs AI directly into MRI and PET brain imaging so pharma clients can detect disease signals faster, manage trials more efficiently and support clinical decisions in disorders where every data point is precious. The opportunity is clear, although profitability and funding still hinge on how one unseen pressure shapes future pricing power and contract depth.
That hidden pressure is already reshaping the risk reward, so line IXICO up against the 1 key reward and 4 important warning signs (2 are major!) to see what might accelerate or stall its momentum.
AIM:IXI Earnings & Revenue History as at Nov 2026
EMV Capital is a London based venture investor backing early and mid stage AI, digital health and diagnostics startups that use data analytics, wearables and software to manage chronic disease and personalise care, with a market value of about £12.6 million.
EMV Capital provides indirect exposure to AI powered healthcare tools through a portfolio of digital health and diagnostics holdings. This portfolio has recently swung to profitability on £1.27 million of half year sales and reported £18.14 million of net income. Future returns depend on how one crucial set of exits and revaluations unfolds.
Those exit and revaluation swings are already in motion, so size up EMV Capital against the 3 key rewards and 2 important warning signs (1 is major!) before those portfolio moves fully reprice expectations
AIM:EMVC Earnings & Revenue History as at Nov 2026
Curious About Alternative Opportunities?
Fresh ideas move first. Potential breakouts can gain momentum while slow capital gets caught watching from the sidelines. Scan new themes that may be under the radar for now and consider them promptly.
Spot cash generative outliers early and track a curated 18 high quality undervalued stocks before valuations move away and the most attractive entry points start dropping out of reach.
Zero in on fast growing AI operators using a filtered 4 AI small caps to follow recent momentum stories before broader attention potentially changes how they are priced.
This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.